Co-Authors
This is a "connection" page, showing publications co-authored by SHREYASKUMAR PATEL and HUSSEIN TAWBI.
Connection Strength
0.907
-
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017 11; 18(11):1493-1501.
Score: 0.635
-
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016 Mar 10; 34(8):786-93.
Score: 0.138
-
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Nat Cancer. 2024 Feb 13.
Score: 0.062
-
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. Cancer. 2017 Jan 01; 123(1):90-97.
Score: 0.037
-
SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma. Cancer. 2016 Mar 15; 122(6):868-74.
Score: 0.035